CAMBRIDGE, UK – 8 March 2018 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.
Bobby is currently Director of Healthcare Investments at Touchstone Innovations, now part of the IP Group plc. He joined Touchstone Innovations (previously Imperial Innovations) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director. Bobby has 17 years’ experience in the Life Science industry covering drug development, business development and venture capital investment. He is a Non-Executive Director of Storm Therapeutics, Enterprise Therapeutics, Artios Pharma, Pulmocide, and Autifony.
Bobby has a PhD in Biology from the University of Virginia and an undergraduate degree in Biochemistry from the University of Rochester.
Commenting on the appointment, Dr Anker Lundemose, Mission’s CEO, said:
“On behalf of the Board I am pleased to welcome Bobby to the Board of Mission Therapeutics. His strong life sciences background and range of experiences within the pharmaceutical and biotechnology sectors will be invaluable as Mission builds its pipeline of first-in-class therapeutic assets across multiple serious disease areas. I would also like to thank Rob for his valuable contribution to Mission and wish him every success in the future.”
FOR MORE INFORMATION:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0) 1223 497199
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
Tel: +44 (0) 20 7457 2020
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.
In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.